Abequolixron (RGX-104) and Durvalumab in Lung Cancer
A Pilot Window of Opportunity Study Evaluating Durvalumab (MEDI4736) in Combination With Platinum Doublet Chemotherapy Followed by Evaluation of Durvalumab (MEDI4736) in Combination With Platinum Doublet Chemotherapy and Abequolixron (RGX-104) in Non-small Cell Lung Cancer
Sponsor: AstraZeneca
Terminated
Sponsor is closing the trial.
Other terminated trials from AstraZeneca
Other Non-Small Cell Lung Cancer trials with similar outcome
This PHASE1 trial investigates Non-Small Cell Lung Cancer and is currently terminated or withdrawn. AstraZeneca leads this study, which shows 6 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Apr 2025 — Present [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2024 — May 2024 [monthly]
Not Yet Recruiting PHASE1
▶ Show 1 earlier version
-
Jul 2023 — Mar 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Rgenix, Inc.
- UNC Lineberger Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .